Tags

Type your tag names separated by a space and hit enter

Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy.
Expert Opin Pharmacother. 2010 Apr; 11(5):723-30.EO

Abstract

IMPORTANCE OF THE FIELD

The prevalence of chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) is increasing. In turn, both CKD and T2DM are associated with increased risk of vascular events and progression to end-stage kidney disease (ESKD). In patients with DM, statin treatment can significantly improve estimated glomerular filtration rate (eGFR) or delay eGFR decline as well as significantly reduce CVD morbidity and mortality. In contrast, statins do not seem to decrease events in patients with advanced decline in kidney function.

AREAS COVERED IN THIS REVIEW

This review considers the effects of statins and other lipid lowering drugs on kidney function and vascular events in patients with CKD and T2DM.

WHAT THE READER WILL GAIN

Greater awareness of the links between CKD, T2DM, kidney function and vascular risk as well as the role of lipid-lowering drugs (mainly statins) in this field.

TAKE HOME MESSAGE

Current evidence points towards the need to prescribe statins in patients with T2DM before a major decline in kidney function occurs.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Athyros VG
Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Hippocration Hospital, Medical School, Thessaloniki, Greece.
Mitsiou EK
No affiliation info available
Tziomalos K
No affiliation info available
Karagiannis A
No affiliation info available
Mikhailidis DP
No affiliation info available

MeSH

AtherosclerosisCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic NephropathiesDyslipidemiasGlomerular Filtration RateHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsKidney Failure, ChronicSeverity of Illness Index

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

20210681

Citation

Athyros, Vasilios G., et al. "Impact of Managing Atherogenic Dyslipidemia On Cardiovascular Outcome Across Different Stages of Diabetic Nephropathy." Expert Opinion On Pharmacotherapy, vol. 11, no. 5, 2010, pp. 723-30.
Athyros VG, Mitsiou EK, Tziomalos K, et al. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother. 2010;11(5):723-30.
Athyros, V. G., Mitsiou, E. K., Tziomalos, K., Karagiannis, A., & Mikhailidis, D. P. (2010). Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opinion On Pharmacotherapy, 11(5), 723-30. https://doi.org/10.1517/14656560903575654
Athyros VG, et al. Impact of Managing Atherogenic Dyslipidemia On Cardiovascular Outcome Across Different Stages of Diabetic Nephropathy. Expert Opin Pharmacother. 2010;11(5):723-30. PubMed PMID: 20210681.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. AU - Athyros,Vasilios G, AU - Mitsiou,Eydoxia K, AU - Tziomalos,Konstantinos, AU - Karagiannis,Asterios, AU - Mikhailidis,Dimitri P, PY - 2010/3/10/entrez PY - 2010/3/10/pubmed PY - 2010/6/18/medline SP - 723 EP - 30 JF - Expert opinion on pharmacotherapy JO - Expert Opin Pharmacother VL - 11 IS - 5 N2 - IMPORTANCE OF THE FIELD: The prevalence of chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) is increasing. In turn, both CKD and T2DM are associated with increased risk of vascular events and progression to end-stage kidney disease (ESKD). In patients with DM, statin treatment can significantly improve estimated glomerular filtration rate (eGFR) or delay eGFR decline as well as significantly reduce CVD morbidity and mortality. In contrast, statins do not seem to decrease events in patients with advanced decline in kidney function. AREAS COVERED IN THIS REVIEW: This review considers the effects of statins and other lipid lowering drugs on kidney function and vascular events in patients with CKD and T2DM. WHAT THE READER WILL GAIN: Greater awareness of the links between CKD, T2DM, kidney function and vascular risk as well as the role of lipid-lowering drugs (mainly statins) in this field. TAKE HOME MESSAGE: Current evidence points towards the need to prescribe statins in patients with T2DM before a major decline in kidney function occurs. SN - 1744-7666 UR - https://www.unboundmedicine.com/medline/citation/20210681/Impact_of_managing_atherogenic_dyslipidemia_on_cardiovascular_outcome_across_different_stages_of_diabetic_nephropathy_ DB - PRIME DP - Unbound Medicine ER -